论文部分内容阅读
目的 研究全身及腹腔化疗对胃癌腹腔游离癌细胞的影响。方法 将2.0×10~4MFC前胃癌细胞注入Balb/c小鼠腹腔内,建立胃癌腹腔游离癌细胞模型。将小鼠分为3组:肿瘤对照组、全身化疗组入腹腔化疗组。全身化疗组经尾静脉注射5—FU1.0mg(0.1ml)只·天,腹腔化疗组注入腹腔5—FU1.0mg(0.6ml)/只·天,均连用5天。于第6日处死全部小鼠,腹水癌细胞计数。结果 肿瘤对照组、全身化疗组及腹腔化疗组游离癌细胞计数分别为1.78±1.05,0.52±0.29及0.26±0.19(单位10~5)。全身化疗组和腹腔化疗组较肿瘤对照组明显减少(P<0.05,P<0.01)。全身化疗组同腹腔化疗组间无差异(P>0.05)。结论 全身化疗及腹腔化疗均可抑制、杀灭胃癌腹腔内游离癌细胞。
Objective To investigate the effects of systemic and intraperitoneal chemotherapy on free gastric cancer cells in the abdominal cavity. Methods 2.0×10~4MFC pre-cancer cells were injected into the abdominal cavity of Balb/c mice to establish a model of gastric cancer cells in the abdominal cavity. The mice were divided into 3 groups: tumor control group, systemic chemotherapy group and intraperitoneal chemotherapy group. In the systemic chemotherapy group, 5-FU 1.0 mg (0.1 ml) was injected into the tail vein for only days, and the intraperitoneal chemotherapy group was injected with 5-FU 1.0 mg (0.6 ml) per day for 5 days. All mice were sacrificed on the 6th day and the ascites cancer cells were counted. Results The free cancer cell counts in tumor control group, systemic chemotherapy group and intraperitoneal chemotherapy group were 1.78±1.05, 0.52±0.29 and 0.26±0.19 (units 10~5), respectively. Compared with the tumor control group, the systemic chemotherapy group and the intraperitoneal chemotherapy group were significantly reduced (P<0.05, P<0.01). There was no difference between the systemic chemotherapy group and the intraperitoneal chemotherapy group (P>0.05). Conclusion Both systemic chemotherapy and intraperitoneal chemotherapy can inhibit and kill gastric cancer cells in the abdominal cavity.